Grifols SA (GRLS)

Currency in EUR
10.875
-0.195(-1.76%)
Real-time Data·
Advertisement
GRLS is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
10.87511.055
52 wk Range
8.43211.730
Key Statistics
Prev. Close
11.07
Open
10.94
Day's Range
10.875-11.055
52 wk Range
8.432-11.73
Volume
215.42K
Average Volume (3m)
1.48M
1-Year Change
7.2449%
Book Value / Share
8.50
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.255
Upside
+40.27%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Grifols SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
2 Hold
1 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.255
(+40.27% Upside)

Earnings

Latest Release
02/11/2026
EPS / Forecast
0.30 / 0.26
Revenue / Forecast
2.04B / 1.97B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.72
Dividend Yield
1.70%
Industry Median 2.62%
Annualised payout
0.19
Paid unevenly
5-Years Growth
-1.53%
Growth Streak

Compare GRLS to Peers and Sector

Metrics to compare
GRLS
Peers
Sector
Relationship
P/E Ratio
13.7x27.0x−0.2x
PEG Ratio
-−0.960.00
Price/Book
1.2x2.5x2.6x
Price / LTM Sales
0.9x3.0x2.7x
Upside (Analyst Target)
39.0%14.6%72.2%
Fair Value Upside
Unlock1.4%12.4%Unlock

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Employees
25000
Market
Spain

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
159.51M23.44%1.82B
Other Institutional Investors
330.70M48.59%3.77B
Public Companies & Retail Investors
190.37M27.97%2.17B
Total
680.58M100.00%7.77B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Brandes Investment Partners, LP9.56%65,036,464742,066
Deria S.A.9.52%64,787,366739,224

People Also Watch

3.270
UNI
-1.57%
28.350
TRE
-5.18%
186.250
ANA
-2.74%
57.850
PHMR
-2.28%
16.160
REDE
+1.51%

FAQ

What Is the Grifols (Madrid: GRLS) Share Price Today?

The Grifols stock price today is 10.875 EUR.

What Stock Exchange Does Grifols (GRLS) Trade On?

Grifols is listed and trades on the Madrid Stock Exchange.

What Is the Ticker (Stock Symbol) for Grifols?

The stock symbol (also called a 'ticker') for Grifols is "GRLS."

Does Grifols Pay Dividends? What’s The Current GRLS Dividend Yield?

Yes, GRLS Pays Dividends to its Shareholders. The current Grifols dividend yield is 1.7%%.

What Is the Current Grifols Market Capitalisation?

As of today, Grifols (Madrid: GRLS) market cap is 7.450B EUR.

What Is Grifols's (GRLS) Earnings Per Share (TTM)?

The Grifols EPS is currently 0.72 (Trailing Twelve Months).

When Is the Next Grifols Earnings Date?

Grifols's next earnings report will be released on 04/03/2027.

Is GRLS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Grifols moving averages and other technical indicators, the daily buy/sell signal for GRLS stock is Sell.

How Many Times Has Grifols Stock Split?

Grifols has split 3 times. (See the GRLS stock split history page for full effective split date and price information.)

How Many Employees Does Grifols Have?

Grifols has 25000 employees, based on their latest Companies House report.

What is the current trading status of Grifols (Madrid: GRLS)?

As of 20/11/2026, Grifols (GRLS) is trading at a share price of 10.875 EUR, with a previous close of 11.070 EUR. The stock has fluctuated within a day range of 10.875 EUR to 11.055 EUR, while its 52-week range spans from 8.432 EUR to 11.730 EUR.

What Is Grifols (GRLS) Price Target According to Analysts?

The average 12-month price target for Grifols is 15.255 EUR, with a high estimate of 23.7 EUR and a low estimate of 9 EUR. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +40.27% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.